l with modest pipeline success, despite our conservative financial estimates. Our $10 TP is based on probability adjusted sum of parts valuation of Tamsulosin and 25% premium for rest of the pipeline. • Tamsulosin XR and DRS differentiated profile should drive uptake — Tamsulosin XR and DRS would be addre